Number 5: The FDA has approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq), the sixth pair of denosumab biosimilars to receive the green light from the agency. The approvals, granted to ...
Major advancements in biosimilars emerge in Europe and Middle East and North Africa (MENA) region, enhancing patient access ...
Australia's adoption of etanercept biosimilars enhances access to rheumatoid arthritis treatments, maintaining treatment ...
Recent approvals and settlements enhance global access to aflibercept biosimilars, improving treatment options for ...
The European Commission (EC) approves new biosimilars for osteoporosis and eye conditions, enhancing treatment options and ...
Biosimilars and generics drive significant health care savings, yet a concerning lack of biosimilar development for biologics set to lose exclusivity in the next 10 years threatens future access and ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
FDA approves Bosaya and Aukelso, expanding affordable denosumab biosimilars for osteoporosis and bone-related cancers, enhancing treatment options.
The European Commission (EC) approves new biosimilars for osteoporosis and eye conditions, enhancing treatment options and patient access across Europe.
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback